Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone

Simple item page
dc.contributor.authorGermanidis, G.
dc.contributor.authorMarcellin, P.
dc.contributor.authorLau, G.
dc.contributor.authorBonino, F.
dc.contributor.authorFarci, P.
dc.contributor.authorHadziyannis, S.
dc.contributor.authorJin, R.
dc.contributor.authorYao, G.B.
dc.contributor.authorPiratvisuth, T.
dc.contributor.authorYurdaydın, C.
dc.contributor.authorDiago, M.
dc.contributor.authorLai, M.Y.
dc.contributor.authorPopescu, M.
dc.contributor.authorPluck, N.
dc.contributor.buuauthorGürel, S.
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi.tr_TR
dc.date.accessioned2022-11-17T07:07:08Z
dc.date.available2022-11-17T07:07:08Z
dc.date.issued2004-10
dc.descriptionBu çalışma, 29 Ekim-02 Kasım 2004 tarihleri arasında Boston[Amerika Birleşik Devletleri]’da düzenlenen 55. Annual Meeting of the American- Association for the Study of Liver Diseases (AASLD)’de bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipAmer Assoc Study Liver Disen_US
dc.identifier.citationGermanidis, G. vd. (2004). “Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone”. Hepatology, 40(4), Supplement 1, 653A-653A.en_US
dc.identifier.endpage653Atr_TR
dc.identifier.issn0270-9139
dc.identifier.issue4, Supplement 1en_US
dc.identifier.startpage653Atr_TR
dc.identifier.urihttp://hdl.handle.net/11452/29471
dc.identifier.volume40tr_TR
dc.identifier.wos000224102101133
dc.indexed.wosSCIEen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalHepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology and hepatologyen_US
dc.subject.wosGastroenterology and hepatologyen_US
dc.titleProfound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) aloneen_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science